C4 Therapeutics (CCCC) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Stifel Nicolaus Keeps Their Buy Rating on C4 Therapeutics (CCCC)
TipRanksSep 16 08:06 ET · Ratings
Morgan Stanley Maintains C4 Therapeutics(CCCC.US) With Hold Rating, Maintains Target Price $8
Moomoo NewsSep 16 06:31 ET · Ratings
Express News | C4 Therapeutics Inc : Evercore ISI Raises Target Price to $10 From $9
ReutersSep 16 02:09 ET
Hold Rating on C4 Therapeutics Amid Early-Stage Drug Development and Market Caution
TipRanksSep 15 06:17 ET · Ratings
C4 Therapeutics Says Protein Degrader Candidate 'Well-Tolerated' in Early Phase 1 Data
MT NewswiresSep 13 11:07 ET
Express News | C4 Therapeutics Inc - Cft1946 Well-Tolerated at All Dose Levels; No Dose-Limiting Toxicities
ReutersSep 13 10:03 ET

Comments

Jaguar8

Sep 8 17:05

NEWS

$C4 Therapeutics (CCCC.US)$
C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024
C4 Therapeutics (Nasdaq: CCCC) announced the release of an abstract containing clinical data from its ongoing Phase 1 trial of CFT1946, a novel BiDAC™ degrader, for mutant BRAF V600 solid tumors.
The abstract, with a data cut-off of April 12, 2024, is available on the ESMO Congress 2024 website. An oral presentation sch...

1

Jaguar8

Jul 16 15:05

NEWS

$C4 Therapeutics (CCCC.US)$
C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024
C4 Therapeutics (Nasdaq: CCCC) has announced that preliminary data from the monotherapy dose escalation portion of their ongoing Phase 1/2 clinical trial of CFT1946 will be presented at the ESMO Congress 2024 in Barcelona, Spain. CFT1946 is a novel BiDAC™ degrader targeting mutant BRAF V600 solid tumors. The present...

Jaguar8

Apr 29 15:03

$C4 Therapeutics (CCCC.US)$
NEWS
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
C4 Therapeutics announced an inducement grant to a new employee under Nasdaq Listing Rule 5635(c)(4). The grant includes non-qualified stock options to purchase 146,880 shares of common stock, with the options vesting over a four-year period. This grant was approved by the Company's Board of Directors and serves as an inducement for the employee to join C4 Therapeutics.

Pushkyy

Mar 13 08:44

$C4 Therapeutics (CCCC.US)$ doesnt look like its gonna go up by much ..

Trytosaveabit

Mar 4 06:06

News

$C4 Therapeutics (CCCC.US)$ C4 Therapeutics Has Entered Into A License Agreement With Merck KGaA, To Exclusively Discover Two Targeted Protein Degraders Against Critical Oncogenic Proteins, C4 Therapeutics Will Receive $16M As Upfront And Is Eligible Of Up $740M In Milestone Payment

1

CCCC C4 Therapeutics

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target